Home > Riviste > Minerva Pediatrics > Fascicoli precedenti > Articles online first > Minerva Pediatrics 2021 Jul 21

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

 

Minerva Pediatrics 2021 Jul 21

DOI: 10.23736/S2724-5276.21.06542-3

Copyright © 2021 EDIZIONI MINERVA MEDICA

lingua: Inglese

Polycystic ovary syndrome in pediatric obesity and diabetes

Elena DONDI 1, Maria TUFANO 2, Maria C. VIGONE 3, Laura LUCACCIONI 4, Gabriella POZZOBON 3, Graziamaria UBERTINI 5, Enza MOZZILLO 6, Maurizio DELVECCHIO 7

1 Department of Pediatrics, S. Andrea Hospital, Vercelli, Italy; 2 Department of Pediatrics and Neonatology, Usl Central Tuscany, Florence, Prato, Italy; 3 Department of Pediatrics, IRCCS San Raffaele Scientific Institute, Milan, Italy; 4 Pediatric Unit, Departmente of Medical and Surgical Sciences for Mothers, Children and Adults, University of Modena and Reggio Emilia, Modena, Italy; 5 Endocrine Unit, Bambino Gesù Children Hospital, IRCCS, Rome, Italy; 6 Section of Pediatrics, Department of Translational Medical Science, Regional Center of Pediatric Diabetes, Federico II University of Naples, Naples, Italy; 7 Metabolic Disorders and Genetic Unit, Giovanni XXIII Children Hospital, Bari, Italy


PDF


INTRODUCTION: Polycystic ovary syndrome is characterized by anovulation (amenorrhea, oligomenorrhea, irregular menstrual cycles) combined with symptoms of androgen excess (hirsutism, acne, alopecia). The clear definition and diagnosis in adolescents could be challenging considering that most of symptoms occur as part of the expected physiological hormonal imbalance of puberty. Therefore, different diagnostic criteria have been elaborated. Polycystic ovary syndrome could be associated to obesity, diabetes mellitus, and metabolic syndrome. In adolescents with polycystic ovary syndrome, adiposity is associated with higher androgen concentrations and greater menstrual irregularity. Polycystic ovary syndrome in youth is considered a risk factor for type 2 diabetes mellitus in adulthood. On the other hand, increased prevalence of polycystic ovary syndrome has been shown in type 1 diabetes mellitus.
EVIDENCE: The treatment of polycystic ovary syndrome in adolescents is controversial considering that adequate trials are lacking. First line treatment comprises lifestyle modification (preferably multicomponent including diet, exercise and behavioural strategies) that should be recommended overall in the patients with polycystic ovary syndrome and overweight, central obesity and insulin resistance. Beyond non-pharmacological therapy, pharmacological agents include combined hormonal contraceptives, metformin and antiandrogens, used separately or in combination. The aim of therapy is to bring back ovulation, to normalize menses, to reduce hirsutism and acne, to reduce weight. Other important goal is the treatment of hyperlipidaemia and of hyperglycaemia.
CONCLUSIONS: This narrative review aims to review the most pertinent literature about polycystic ovary syndrome in adolescents with obesity or diabetes. We overviewed the diagnostic criteria, the pathophysiology and the possible treatment approaches.


KEY WORDS: Polycystic ovary syndrome; Obesity; Diabetes mellitus; Adolescence

inizio pagina